160 related articles for article (PubMed ID: 24560135)
1. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
[TBL] [Abstract][Full Text] [Related]
2. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.
Schneider JG; von Eynatten M; Parhofer KG; Volkmer JE; Schiekofer S; Hamann A; Nawroth PP; Dugi KA
Atherosclerosis; 2004 Aug; 175(2):325-31. PubMed ID: 15262189
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Huptas S; Geiss HC; Otto C; Parhofer KG
Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
Hamilton SJ; Chew GT; Davis TM; Watts GF
Clin Sci (Lond); 2010 Feb; 118(10):607-15. PubMed ID: 20047560
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
7. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
8. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.
Huang XS; Zhao SP; Bai L; Hu M; Zhao W; Zhang Q
Br J Pharmacol; 2009 Oct; 158(3):706-12. PubMed ID: 19694729
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
Wong V; Stavar L; Szeto L; Uffelman K; Wang CH; Fantus IG; Lewis GF
Atherosclerosis; 2006 Feb; 184(2):348-55. PubMed ID: 15998521
[TBL] [Abstract][Full Text] [Related]
12. Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus.
Amudha K; Choy AM; Mustafa MR; Lang CC
Cardiovasc Ther; 2008; 26(4):253-61. PubMed ID: 19035876
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
14. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
16. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
Cree MG; Zwetsloot JJ; Herndon DN; Qian T; Morio B; Fram R; Sanford AP; Aarsland A; Wolfe RR
Ann Surg; 2007 Feb; 245(2):214-21. PubMed ID: 17245174
[TBL] [Abstract][Full Text] [Related]
17. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
18. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
19. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Melenovsky V; Wichterle D; Simek J; Malik J; Haas T; Ceska R; Malik M
Am J Cardiol; 2003 Aug; 92(3):337-41. PubMed ID: 12888150
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Su Y; Xu Y; Sun YM; Li J; Liu XM; Li YB; Liu GD; Bi S
J Cardiovasc Pharmacol; 2010 Jan; 55(1):21-5. PubMed ID: 19786892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
